Effect of Agomelatine and Fluoxetine on HAM-D Score, Serum Brain-Derived Neurotrophic Factor, and Tumor Necrosis Factor- Level in Patients With Major Depressive Disorder With Severe Depression

Evidence suggests that neurotrophic factors, inflammatory markers, and circadian rhythm dysfunctions could be involved in pathophysiology of major depressive disorder. This study evaluated the efficacy and tolerability of agomelatine, a melatonergic drug, and fluoxetine (positive comparator) and their effect on serum brain-derived neurotrophic factor (BDNF) and tumor necrosis factor (TNF)- level in patients having major depressive disorder with severe depression. In the present study, we chose TNF- and BDNF because reduction of TNF- and rise in BDNF levels are linked with improvement in major depressive disorder. Patients with Hamilton Rating Scale for Depression (HAM-D) score 25 were treated with agomelatine or fluoxetine and followed up for 12 weeks. In the agomelatine group, the HAM-D score, BDNF level, and TNF- level at the start of treatment were 31.1 +/- 1.88 ng/mL, 2.44 +/- 0.38 ng/mL, and 512.5 +/- 86.2 pg/mL, respectively, which significantly changed to 13.67 +/- 2.22 ng/mL, 2.87 +/- 0.44 ng/mL, and 391.64 +/- 104.8 pg/mL, respectively (P < .05 for all 3 measures), at 12 weeks. In the fluoxetine group, the HAM-D score, BDNF level, and TNF- level at the start of treatment were 30.83 +/- 2.60 ng/mL, 2.54 +/- 0.37 ng/mL, and 554.14 +/- 46.8 pg/mL, respectively, which significantly changed to 13.67 +/- 1.79 ng/mL, 3.07 +/- 0.33 ng/mL, and 484.15 +/- 49.9 pg/mL, respectively (P < .05 for all 3 measures) at 12 weeks. The BDNF level was significantly increased posttreatment with both drugs, and TNF- level fell significantly more with agomelatine compared to fluoxetine. Thus, chronic neuroinflammatory biomarkers contribute to circuitry dysregulation in depression. Trophic factors repair dysfunctional circuits in depression. Both treatments were found to be safe and well tolerated.